BridgeBio Pharma Operating Margin 2018-2026 | BBIO
Current and historical operating margin for BridgeBio Pharma (BBIO) over the last 10 years. The current operating profit margin for BridgeBio Pharma as of March 31, 2026 is -144.39%.
| BridgeBio Pharma Operating Margin Historical Data | |||
|---|---|---|---|
| Date | TTM Revenue | TTM Operating Income | Operating Margin |
| 2026-03-31 | $0.58B | $-0.53B | -90.36% |
| 2025-12-31 | $0.50B | $-0.52B | -103.98% |
| 2025-09-30 | $0.36B | $-0.61B | -171.55% |
| 2025-06-30 | $0.24B | $-0.66B | -276.79% |
| 2025-03-31 | $0.13B | $-0.70B | -545.31% |
| 2024-12-31 | $0.22B | $-0.59B | -267.57% |
| 2024-09-30 | $0.22B | $-0.55B | -250.00% |
| 2024-06-30 | $0.22B | $-0.51B | -233.33% |
| 2024-03-31 | $0.22B | $-0.48B | -219.63% |
| 2023-12-31 | $0.01B | $-0.61B | -6070.00% |
| 2023-09-30 | $0.01B | $-0.56B | -5590.00% |
| 2023-06-30 | $0.01B | $-0.53B | -8833.33% |
| 2023-03-31 | $0.08B | $-0.46B | -594.87% |
| 2022-12-31 | $0.08B | $-0.51B | -656.41% |
| 2022-09-30 | $0.09B | $-0.55B | -616.85% |
| 2022-06-30 | $0.09B | $-0.57B | -625.27% |
| 2022-03-31 | $0.07B | $-0.58B | -821.13% |
| 2021-12-31 | $0.07B | $-0.58B | -836.23% |
| 2021-09-30 | $0.06B | $-0.54B | -960.71% |
| 2021-06-30 | $0.06B | $-0.51B | -820.97% |
| 2020-09-30 | $0.02B | $-0.43B | -1936.36% |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | Medical - Generic Drugs | $14.460B | $0.502B |
| BridgeBio Pharma Inc. is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio Pharma Inc. is based in PALO ALTO, Calif. | |||
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Teva Pharmaceutical Industries (TEVA) | Israel | $35.437B | 10.97 |
| Dr Reddy's Laboratories (RDY) | India | $11.109B | 17.29 |
| Aspen Pharmacare (APNHY) | South Africa | $3.708B | 0.00 |
| Supernus Pharmaceuticals (SUPN) | United States | $2.918B | 22.33 |
| Bausch Health Cos (BHC) | Canada | $2.086B | 1.50 |
| Taysha Gene Therapies (TSHA) | United States | $1.290B | 0.00 |
| Amphastar Pharmaceuticals (AMPH) | United States | $0.924B | 7.28 |
| Personalis (PSNL) | United States | $0.630B | 0.00 |
| Assembly Biosciences (ASMB) | United States | $0.451B | 0.00 |
| Sol-Gel Technologies (SLGL) | Israel | $0.210B | 0.00 |
| Metagenomi Therapeutics (MGX) | United States | $0.052B | 0.00 |
| Evoke Pharma (EVOK) | United States | $0.019B | 0.00 |
| Teligent (TLGT) | United States | $0.000B | 0.00 |